

References

- Adami HO, Chow WH, Nyren O, Berne C, Linet MS, Ekblom A, Wolk A, McLaughlin JK, Fraumeni Jf Jr.** Excess risk of primary liver cancer in patients with DM. *J natl cancer inst* 1996;88:1472-1477.
- Ahn J and Flamm SL.** HCC. *dis mon* 2004; 50:556-573.
- Aizawa Y, Shibamoto Y, Takagi I, Zeniya M and Toda G.** Analysis of factors affecting the appearance of HCC in patients with chronic hepatitis C. *Cancer* 2000, 89(1):53-59.
- Badvie S.** HCC. *postgrad med J* 2000;76:4-11.
- Barbara L, Benzi G, Gaiani S, Fusconi F, Zironi G, Siringo S, Rigamonti A, Barbara C, Grigioni W, Mazziotti A, et al.** Natural history of small untreated hepatocellular carcinoma in cirrhosis: a multivariate analysis of prognostic factors of tumour growth rate and patient survival. *hepatology* 1992;16:132-137.
- Befeler AS and Di Bisceglie AM.** Hepatocellular carcinoma: diagnosis and treatment. *Gastroenterology* .2002;122 (6):1609-19.
- Berger DH, Carrasco CH, Hohn DC et al.** Hepatic artery chemoembolization or embolization for primary and metastatic liver tumours. post treatment management and complications. *J surg oncol* 1995;60:116-121.
- Berr F, Bruix J, Hauss J, Wands J, Wittekind Ch, and Wands J.eds.** Malignant liver tumours ; basic concepts and clinical management , Kluwer Academic Publishers BV and Falk Foundation. Dordrecht 2003 67-74.
- Bianch L.** Glycogen storage disease I and hepatocellular tumours. *Eur J Pediatr*.2000: 152: 263-270.
- Bismuth H, Chiche L, Adam R, Castaing D, Diamond T and Dennison A.** Liver resection versus transplantation for

hepatocellular carcinoma in cirrhosis. *Ann Surg* 1993;218(2) : 145-151.

Bismuth H ,Majno PE and Adam R. Liver transplantation for hepatocellular carcinoma. *Semin Liver Dis* 1999;19(3):311-322.

Bosch FX , Ribes J and Borrás J. Epidemiology of primary liver cancer. *Semin. Liver Dis.* 1999;19(3),271-285.

Bosch FX, Ribes J , Diaz M and Cleries R. Primary liver cancer. worldwide incidence and trends. *gastroenterology* 2004;127:S5-S16.

Bravi F, Bosetti C, Tavani A, Bagnardi V, Gallus S, Negri E, Franceschi S, La Vecchia C. Coffee drinking and HCC risk. a meta analysis .*hepatology* 2007;46:430-435.

Breedis C, Young G. The blood supply of neoplasms in the liver. *Am J Pathol* 1954; 30:969.

Breinholt V , Schimerlik M , Dashwood R and Baily GS . Mechanisms of chlorophyllin anticarcinogenesis against aflatoxin B1. Complex formation with the carcinogen. *chem ros toxicol* 1995 ;8:506-14.

Bruix J , Sherman M , Llovet JM , Beaugrand M, Lencioni R , Burroughs AK, Christensen E, Pagliaro L , Colombo M and Rodes J. EASL Panel of experts on HCC. Clinical management of hepatocellular carcinoma .Conclusions of the Barcelona -2000 EASL conference .European association for the study of the liver. *J Hepatol* 2001 ;35(3):421-430.

Bruix J ,Sala M, Llovet JM. Chemoembolization for hepatocellular carcinoma. *Gastroenterology* 2004 ;127:S179:S188.

Bruix J, Llovet JM. Prognostic prediction and treatment strategy in hepatocellular carcinoma. *Hepatology* 2002; 35(3):519-524.

Bruix J, Sherman M, Llovet JM et al. Clinical management of HCC .Conclusions of the Barcelona 2000 EASL conference. European association for the study of the liver. *J hepatol* 2001; 35:421-430.

- Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, Christensen E, Pagliaro L, Colombo M, Rodes J.** Clinical management of HCC. conclusions of the Barcelona 2000 EASL conference .European Association for the Study of the Liver. J hepatol 2001;35:421-430.
- Bruno S, Silini E, Crosigani A, Borzio F, Leandro G, Bono F et al.** HCV genotypes and the risk of HCC in cirrhosis. A prospective study .hepatology 1997; 25:754-8.
- Buscarini L , Di Stasi M and Buscarini E.** Clinical presentation , diagnostic workup and therapeutic choices in two consecutive series of patients with HCC. Oncology 2000: 53, 204-209.
- Buscarini L, Buscarini E and Di Stasi M.** Percutaneous radiofrequency ablation of small hepatocellular carcinoma: long term results. Eur Radiol . 2001;11(6):914-921.
- Chang MH.** Decreasing incidence of HCC among children following universal hepatitis B immunization. Liver Int 2003, 23: 309-315.
- Chang M-H.** Decreasing incidence of hepatocellular carcinoma among children following universal hepatitis B immunization. liver int. 2003;23:309-14.
- Chen MS, Li JQ, Zhang YQ, Lu LX, Zhang WZ, Yuan YF, Guo YP, Lin XJ and Li GH.** High dose iodized oil transcatheter arterial chemoembolization for patients with large hepatocellular carcinoma. world J gastroenterology 2002 ; 8: 74-78.
- Collier J and Sherman M.** Screening for hepatocellular carcinoma. hepatology 1998;27(1):273-278.
- Colombo M.** HCV and HCC. Semin Liver Dis 1999, 19: 263-269.

- Daniele B, Bencivenga A, Megna AS and Tinessa V** .Alpha fetoprotein and ultrasonography screening for HCC.gastroenterology 2004;127:S108-S112.
- Davila JA , Morgan RO, Shaib Y, McGlynn KA and El Serag HB**.HCV infection and the increasing incidence of HCC. A population based study .gastroenterology 2004 ;127:1372-80.
- Di Bisceglie A , Carithers RL and Gores G**.HCC.hepatology 1998;28:1161-1165.
- Di Bisceglie AM**.Epidemiology and clinical presentation of HCC.J vas interv radiol 2002; 13:S169-S171.
- Donato F, Boffetta P and Puoti M**.A meta analysis of epidemiological studies on the combined effect of hepatitis B and C virus infections in causing HCC.int J cancer 1998;75:347-354 .
- EL Far MA , Atwa MA , Yahya RS , El Basuni MA**. Evaluation of serum levels of P53 in HCC in Egypt. Clin Chem Lab Med 2006 ; 44:653-656.
- El-Serag HB (2001)**: Epidemiology of HCC. clin. Liver dis. ; 5:87-107.
- El-Serag HB**. HCC: an epidemiologic review. J. clin Gastroenterol 2002;35(Suppl 2):S72-78.
- El-Zayadi AR (2006)**:Heavy smoking and liver. world J gastroenterol;12(38):6098-6101.
- El-Zayadi AR , Badran HM , Barakat EM et al (2005)**: HCC in Egypt – a single centre study over a decade . world J gastroenterol; 11(33):5193-5198.
- Ezzat S , Abdel-Hamid M , Eissa SA , Mokhtar N , Labib NA , El-ghorory L , Michail NN , Abdel-Hamid A , Hifnawy T , Strickland GT , Loffredo CA**.Associations of pesticides , HCV , HBV and HCC in Egypt. Int J Hyg Environ Health 2005 ; 208: 329-339.

- Fan J, Wu ZQ, Tang ZY, Zhou J, Qiu SJ, Ma ZC, Zhou XD and Ye SL.**Multimodality treatment in hepatocellular carcinoma patients with tumour thrombi in portal vein. world J gastroenterology 2001;7:28-32.
- Farber E.** Approaches to cancer prevention. introduction and perspective.proc am assoc cancer res 1988;29:527-8.
- Feitelson M.** HBV infection and primary HCC. Clin Microbiol Rev 1992 : 5: 275-301.
- Frazer C.** Imaging of HCC.J gastroenterology hepatol 1999;14:750-756.
- Gamal Esmat , M.K.Shaker , Runia F. El Folly , Ashraf Omer , Wafaa El Metanawy , A. El dorry , M.M.Tawfik , Imam Waked , Mohsen Salama , Amr Helmy , Mahmoud El Meteny , Refaat Refaat Kamel , Emad Hamada , Heba El Zawahry and Tawhida Y.Abd El Ghaffar.** Toward an Egyptian guidline from screening to treatment of HCC (part II).Septembre 2009 , vol . 8 , no. 3 , 108-109.
- Garcia Samaniego J , Rodriguez M, Berenguer J, Rodriguez-Rosado R, Carbo J, Asensi V and Soriano V.** HCC in HIV infected patients with chronic hepatitis C.am J gastroenterol 2001; 96: 179-183.
- Gondolesi G, Munoz K, Matsumoto C, Fifhbein T, Sheiner P , Emre S, Miller C and Schwartz ME.**Hepatocellular carcinoma: a prime indication for living donor liver transplantation .J gastrointest.surg 2002;6(1):102-107.
- Groopman JD, Scholl P and Wang JS.**Epidemiology of human aflatoxin exposure and their relationship to liver cancer.prog clin boil res 1996;395:211-222.
- Group d Etude et de Traitment du carcinoma hepatocellulaire.**A comparison of lipidol chemoembolization and conservative

treatment for unresectable hepatocellular carcinoma. *N Engl J Med* 1995;332(19):1256-1261.

Jiang HC , Liu LX, Piao DX, Xu J, Zheng M, Zhu AL, Qi SY, Zhang WH and Wu LF. Clinical short term results of radiofrequency ablation in liver cancer. *world J gastroenterology* 2002 ; 8:624-630.

Jiang YF, Yang ZH and Hu JQ. Recurrence or metastasis of HCC . predictors , early detection and experimental antiangiogenic therapy. *world J gastroenterology* 2000 ; 6:61-65.

Jonas S , Bechstein WO, Steinmuller T, Herrmann M, Radke C , Berg T , Settmacher U and Neuhaus P. Vascular invasion and histopathologic grading determine outcome after liver transplantation for hepatocellular carcinoma in cirrhosis. *Hepatology* 2001 ;33(5):1080-1086.

Kao JH, Chen PJ, Lai MY, Chen DS. Basal core promoter mutations of HBV increase the risk of HCC in hepatitis B carriers. *gastroenterology* 2003;124:327-334.

Kasahara A , Hayashi N , Mochizuki K , Takayanagi M , Yoshioka K , Kakumu S, Iijima A, Urushihara A , Kiyosawa K , Okuda M, Hino K and Okita K. Risk factors for HCC and its incidence after interferon treatment in patients with chronic hepatitis C .Osaka Liver Disease Study Group. *Hepatology* 1998, 27: 1394-1402.

Kasahara A, Hayashi N, Mochizuki K, Takayanagi M, Yosh ioka K, Kakumu S et al. Risk factors for HCC and its incidence after interferon treatment in patients with chronic HCV infection. *hepatology* 1998;27:1439-402.

Kew MC. HCV and HCC in developing and developed countries. *vir hepatit rev* 1998;4:259-69.

- Kew MC.** Synergistic interaction between aflatoxin B1 and HBV in hepatocarcinogenesis.liver int.2003;23:1-5.
- Kim CK,Lim JH and Lee WJ.**Detection of hepatocellular carcinomas and dysplastic nodules in cirrhotic liver: accuracy of ultrasonography in transplant patients. J Ultrasound Med 2001;20(2):99-104.
- Kojiro M.** The evolution of pathologic features of hepatocellular carcinoma .in:A.J.Zuckerman, I.K.Mushahwar, eds .Perspectives in medical virology. E.Tabor,ed. Viruses and liver cancer . Elsevier Science B.V,2002:113-122.
- Kubo S, Nishiguchi S, Hirohashi K et al.**Effects of long term postoperative interferon alpha therapy on intrahepatic recurrence after resection of hepatitis C virus related HCC.A randomized controlled trial.ann intern med 2001 ; 134:963-967.
- Kudo M.**Imaging diagnosis of HCC and premalignant / borderline lesions. semin liver dis 1999,19:297-309.
- Kuper H, Tzonou A, Kaklamani E, Hsieh CC, Lagiou P, Adami HO, Trichopoulos D, Stuver SO.**Tobacco smoking, alcohol consumption and their interaction in the causation of HCC.int J cancer 2000;85:498-502.
- Lai CL, Wu PC, Chan GC et al.**Doxorubicin versus no antitumour therapy in inoperable HCC.a prospective randomized trial.cancer 1988;62:479.
- Leung TW, Patt YZ, Lau WY et al.**Complete pathological remission is possible with systemic combination chemotherapy for inoperable HCC.clin cancer res 1999;5:1676.
- Liaw YF , Yai DI, Chu CM, Lin DY, Sheen IS, Chen TJ and Pao CC.**Early detection of HCC in patients with chronic type B hepatitis. A prospective study. gastroenterology 1986;90:263-267.

- Liaw YF, Tai DI, Chu CM, Lin DY, Sheen IS, Chen TJ, and Pao cc.** Early detection of hepatocellular carcinoma in patients with chronic type B hepatitis .A prospective study. *gastroenterology* 1986;90(2):263-267.
- Lin DY, Liaw YF, Lee TY and Lai CM .** Hepatic arterial embolization in patients with unresectable hepatocellular carcinoma. A randomized control trial. *gastroenterology* 1988;94(2):453-456.
- Lin DY, Lin SM and Liaw YF.** Non surgical treatment of HCC. *J gastroenterology hepatol* 1997;12:S319.
- Liu CJ and Kao JH.** HBV related HCC. Epidemiology and pathogenic role of viral factors. *J chin med assoc* 2007;70:141-145.
- Liu CJ, Chen BF, Chen PJ, Lai MY, Huang WL, Kao JH and Chen DS.** Role of HBV precore/core promoter mutations and serum viral load on noncirrhotic HCC .A case control study. *J infect dis* 2006;194:594-599.
- Livraghi T, Giorgio A , Martin G, Salmi A, de Sio I, Bolondi L, Pompili M , Brunello F, Lazzaroni S, Torzilli G, et all.** Hepatocellular carcinoma and cirrhosis in 746 patients: long term results of percutaneous ethanol injection. *Radiology* 1995;197(1):101-108.
- Livraghi T, Giorgio A, Marin G et al.** HCC and cirrhosis in 746 patients. Long term results of percutaneous ethanol injection. *radiology* 1995;197:101-108.
- Livraghi T, Goldberg SN, Lazzaroni S et al.** Small HCC. Treatment with RFA versus ethanol injection. *radiology* 1999;210:655-661.
- Llovet J , Burroughs A and Bruix J.** Hepatocellular carcinoma. *lancet* 2003.

Llovet JM and Beaugrand M.Hepatocellular carcinoma present status and future prospects.J hepatol 2003 ; 38: SUPP 1 : S 136-149.

Llovet JM and Bruix J.Systemic review of randomized trials for unresectable hepatocellular carcinoma. Chemoembolization improve survival. hepatology 2003 ;37(2):429-442.

Llovet JM, Bru C and Bruix J. Prognosis of hepatocellular carcinoma. the BCLC staging classification.Semin Liver Dis 1999;19(3):329-338.

Llovet JM, Bru C and Bruix J.Prognosis of HCC.the BCLC staging system.semin liver dis 1999;19:329-338.

Llovet JM, Burrel M, Sala M et al.MRI angiography is superior to helical CT for detection of early hepatocellular carcinoma prior to liver transplantation .A blind coparison with histologic correlation.hepatology 2002;36:303A.

Llovet JM, Fuster J, Bruix J.Intention to treat analysis of surgical treatment for early hepatocellular carcinoma. Resection versus transplantation. hepatology 1999;30(6):1434-1440.

Llovet JM, Real MI, Montana X, Planas R, Coll S , Aponte J, Ayuso C, Sala M, Muchart J, Sola R , Rodes J and Bruix J.Arterial embolization or chemoembolization versus symptomatic treatment in patients with unresectable hepatocellular carcinoma. A randomized control trial .lancet 2002 ; 359(9319):1734-1739.

Llovet JM, Sala M, Castells L, Suarez Y, Vilana R ,Bianchi Ll, Ayuso C, et al.Randomized control trial of interferon treatment for advanced hepatocellular carcinoma. hepatology 2000;31:1-5.

LlovetJM, Bustamante J, Castells A, Vilana R, Ayuso Mdel C, Sala M, Bru C, Rodes J and Bruix J.Natural history of untreated

nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials. *hepatology* 1999;29(1): 62-67.

Lo CM, Ngan H , Tso WK , Liu CL, Lam CM, Poon RT, Fan ST and Wong J. Randomized control trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. *hepatology* 2002 ; 35(5): 1164-1171.

M.Tawfik , S.Abdel Fatah , A.Helmy , A.Khalil , A.El dorry , R. El dosoki , A.seleem and H. Abdel Fatah. Assesment of basic guidline for management of HCC in Egyptian patients. Septembre 2006 , vol . 26, supp. 1 , 70.

Makuuchi M, Kosuge T, Takayama T, Yamazaki S, Kakazu T , Miyagawa S, Kawasaki S. Surgery for small liver cancers. *Semin Surg Oncol* 1993;9(4):298-304.

Manns M, Paul P and Kabicka S. HCC. *Digestion* 1997 : 58, 69-75.

Mazzaferro V, Regalia E , Doci R, Andreola S, Pulvirenti A ,Bozzetti F, Montalto F , Ammatuna M, Morabito A and Gennari L. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. *N Engl J Med* 1996;334(11):693-699.

Mazzaferro V,Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F, Montalto F, Ammatuna M, Morabito A and Gennari L. Liver transplantation for the treatment of small HCC in patients with cirrhosis. *n eng J med* 1996;334:693-699.

Michielsen PP, Francque SM and van Dongen JL. Viral hepatitis and HCC. *world J surg oncol* 2005;3:27.

Minami M, Poussin K, Kew M, Okanoué T, Brechot C, Paterlini P. Precore/core mutations of HBV in HCC developed in noncirrhotic livers. *gastroenterology* 1996; 111:691-700.

- Montalto G, Cervello M, Giannitrapani L, Dantona F, Terranova A and Castagnetta LA.** Epidemiology, risk factors and natural history of HCC. *ann n y acad sci* 2002 ;963:13-20.
- Montalto G, Cervello M, Giannitrapani L, Dantona F, Terranova A and Castagnetta LA.** Epidemiology , risk factors and natural history of HCC. *Ann N Y Acad Sci* 2002 : 963: 13-20.
- Muto M, Moriwaki H, Ninomiya M , Adachi S, Saito A, Takasaki KT et al.** Prevention of second primary tumours by an acyclic retinoid , polyprenoic acid , in patients with HCC. *N eng J med* 1996;334:1561-7.
- Muto Y, Moriwaki H and Saito A.** Prevention of second primary tumours by an acyclic retinoid in patients with HCC. *n eng J med* 1999;340:1046-7.
- Muto Y, Moriwaki H, Ninomiya M et al.** Prevention of second primary tumours by an acyclic retinoid , polyprenoic acid , in patients with hepatocellular carcinoma. Hepatoma prevention study group. *n engl J med* 1996;334:1561.
- Nagashima I, Hamada C, Naruse K et al.** Surgical resection of small HCC. *surgery* 1996 ;119:40-45.
- NairS, Shiv Kumar K, Thuluvath PJ , ShivakumarKS and Shiva Kumar K .** Mortelity from hepatocellular and biliary cancers. Changing epidemiological trends. *Am J gastroenterol* 2002;97(1):167-171.
- Ni YH, Chang MH, Wang KJ, Hsu HY, Chen HL, Kao JH, Yeh SH, Jeng YM, Tsai KS and Chen DS.** Clinical relevance of HBV genotype in children with chronic infection and HCC. *gastroenterology* 2004;127:1733-1738.
- Nishiguchi S, Kuroki T, Nakatani S et al.** Randomized trial of effects of interferon alpha on incidence of HCC in chronic active hepatitis C with cirrhosis. *lancet* 1995;346:1051.

- Oda T, Tsuda H, Scarpa A, Sakamoto M and Hirohashi S.** P52 gene mutation spectrum in HCC. *cancer res* 1992;52:6358-6364.
- Ohata K, Hamasaki K , Toriyama K, Ishikawa H, Nakao K and Eguchi K.** High viral load is a risk factor for HCC in patients with chronic HBV infection. *J Gastroenterol Hepatol* 2004 , 19: 670-675.
- Ohoto M , Yoshikawa M and Saito H.** Non surgical treatment of HCC in cirrhotic patients. *World J. Surg.* 1995 : 19 : 42-46.
- Okano H , Shiraki K , Inoue H , Deguchi M, Sugimoto K , Sakai T , Ohmori S , Murata K, Nakano T , Yamakado K and Takeda K.** Treatment of HCC and the exacerbation of liver function. *Int J Oncol* 2001 , 19, 1279-1282.
- Okuda K, Ohtsuki T , Obata H, Tomimatsu M, Okazaki N, Hasegawa H, Nakajima Y and Ohnishi K.** Natural history of hepatocellular carcinoma and prognosis in relation to treatment. study of 850 patients. *cancer* 1985 ;56(4)918-928.
- Okuda K, Ohtsuki T, Obata H et al.** Natural history of HCC and prognosis in relation to treatment. study of 850 patients. *cancer* 1985;56:918-928.
- Okuda K.** HCC. *J hepatol* 2000;32:225-237.
- Okuno M, Kojima S and Moriwaki H.** Chemoprevention of HCC. concept , progress and perspectives. *J gastroenterology hepatol* 2001 ;16:1329-35.
- Parikh S and Hyman D.** HCC. A guide for the interest. *am J med* 2007 ;120:194-202.
- Patt YZ, Charnsangavej C, Yoffe B et al.** Hepatic arterial infusion of floxuridine ,leucovorin,doxorubicin and cisplatin for HCC .Effects of hepatitis B and C viral infections on drug toxicity and patient survival. *J clin oncol* 1994;12:1204.

- Pawarode A , Voravud N , Sruiranpong V , Kullavanijaya P and Patt YZ.** Natural history of untreated primary HCC. A retrospective study of 157 patients. *am J clin oncol* 1998; 21:386-91.
- Pelletier G, Roche A, Ink O, Anciaux ML, Derhy S, Rougier P, Lenoir C, Attali P and Ettienne JP.** A randomized trial of hepatic arterial chemoembolization in patients with unresectable hepatocellular carcinoma. *J hepatol* 1990 ;11 (2):181-184.
- Qin LX and Tang ZY.** The prognostic molecular markers in hepatocellular carcinoma. *world J gastroenterology* 2002;8:385-392.
- Rahman El-Zayadi A, Abaza H, Shawky S, Mohamed MK, Selim OE , Badran HM.** Prevalence and epidemiological features of HCC in Egypt – a single centre experience. *Hepatol Res* 2001 ; 19:170-179.
- Rossi S, Di Stasi M, Buscarini E , Quaretti P, Garbagnati F , Squassante L, Paties CT , Silverman DE and Buscarini L.** Percutaneous RF interstitial thermal ablation in the treatment of hepatic cancer. *AJR* 1996 ;167(3):759-768.
- Rossi S, DI Stasi M, Buscarini E et al.** Percutaneous RF interstitial thermal ablation in the treatment of hepatic cancer. *am J roentgenol* 1996;167:759-768.
- Ryder SD.** Guidelines for the diagnosis and treatment of HCC in adults. *gut* 2003;52(suppl 3):1-8.
- Sangiovanni A, Del Nino E , Fasani P, De Fazio C, Ronchi G, Romeo R, Morabito A, De Franchis R and Colombo M.** Increased survival of cirrhotic patients with a hepatocellular carcinoma detected during surveillance. *gastroenterology* 2004;126:1005-1014.

- Sato Y , Nakata K , Kato Y , Shima M et al.**Early detection of HCC based on altered profile of alpha fetoprotein.N Eng J Med 1997; 328, 1802-1806.
- Schafer DF and Sorreli MF.** Hepatocellular carcinoma. lancet 1999;353:1253-1257.
- Seeff LB and Hoofnagle JH.** Epidemiology of HCC in areas of low hepatitis B and hepatitis C endemicity.oncogene 2006;25:3771-3777.
- Sherman M.**HCC. Epidemiology, risk factors and screening.semin liver dis 2005;25:143-154.
- Shiratori Y, Ito Y, Yokosuka O et al.**Antiviral therapy for cirrhotic hepatitis C.Association with reduced HCC development and improved survival.ann intern med 2005;142:105-114.
- Skamoto M and Hirohashi S.** Natural history and prognosis of adenomatous hyperplasia and early hepatocellular carcinoma. Multiinstitutional analysis of 53 nodules followed up for more than 6 months and 141 patients with single early hepatocellular carcinoma treated by surgical resection or percutaneous ethanol injection.Jp J Clin Oncol 1998; 28(10):604-608.
- Sotiropoulos GC, Malago M, Molmenti E et al** .Liver transplantation for HCC in cirrhosis. Is clinical tumour classification before transplantation realistic.transplantation ? 2005;79:483-487.
- Stefanini GF, Amorati P, Biselli M et al.**Efficacy of transarterial targeted treatment on survival of patients with HCC. cancer 1995; 75:2427-2434.
- Sudakin DL.**Dietary aflatoxin exposure and chemoprevention of cancer . A clinical review.J toxicol clin toxicol.2003;41:195-204.
- Sun Z,Lu P, Gail MH, Pee D, Zhang Q, Ming L, Wang J, Wu Y, Liu G, Wu Y and Zhu Y.**Increased risk of hepatocellular carcinoma in

males HBsAg carriers with chronic hepatitis who have detectable aflatoxin metabolite M1. *hepatology* 1999;30(2):379-383.

Surgiura N, Takara K and Ohato M. Treatment of small HCC by percutaneous injection of ethanol into the tumour with real time monitoring. *Acat Hepatol* 1983, 24:920.

Sven J , Bechstein B and Thomas S. Vascular invasion and histopathologic grading determine outcome after liver transplantation for HCC in cirrhosis. *Hepatology* 2001 , 33: 1080-1086.

Tabor E. Interferon for preventing and treating HCC associated with hepatitis B and hepatitis C viruses. *dig liv dis* 2003 ;35:297-305.

Takayama T, Makuuchi M, Hirohashi S, Sakamoto M, Yamamoto J, Shimada K, Kosuge T, Okada S, Takayasu K and Yamasaki S. Early hepatocellular carcinoma as an entity with high rate of surgical cure. *hepatology* 1998;28(5):1241-1246.

Takayasu K, Suzuki M, Uesaka K et al. Hepatic artery embolization for inoperable HCC prognosis and risk factors. *cancer chemother pharmacol* 1989;23:S123-125 .

Tanaka K, Nakamura S, Numata K et al. HCC. treatment with percutaneous ethanol injection and transcatheter arterial embolization. *radiology* 1992; 185:457-460.

Tang ZY. Hepatocellular carcinoma: cause, treatment and metastasis. *World J gastroenterology* 2001;7:445-454.

Terada T , Nakanuma Y and Kawai K. Small HCC presenting as intrabiliary pedunculated polyp and obstructive jaundice. *J Clin Gastroenterol* . 1989, 11: 578.

Teratani T, Ishikawa T, Shiratori Y, Shiina S, Yoshida H, Imamura M, Obi S , Sato S , Hamamura K and Omata M. HCC in elderly patients: beneficial therapeutic efficacy using

percutaneous ethanol injection therapy. *Cancer* 2002, 95: 816-823.

The Cancer Of Liver Italian Program (CLIP) Investigators. A new prognostic system for HCC .A retrospective review of 435 patients. *hepatology* 1998 ; 28 : 751-755.

Trevisani F, D Intino P, Morselli-Labate A et al. Serum alpha fetoprotein for diagnosis of HCC in patients with chronic liver disease. Influence of HBsAg and anti HCV status. *J hepatol* 2001;34:570-575.

Tsai FC, Liu CJ, Chen CL, Chen PJ, Lai MY, Kao JH and Chen DS. Lower serum viral loads in young patients with hepatitis B virus related HCC. *J viral hepat* 2007;14:153-160.

Tsukuma H , Hiyama T , Tanaka S , Nakao M and Kitamura T. Risk factors for HCC among patients with chronic liver diseases. *N. Engl. J. Med.* 1993: 328, 797-801.

Tsukuma H, Hiyama T, Tanaka S, Nakao M, Yabuuchi T, Kitamura T, Nakanishi K, Fujimoto I , Inoue A, Yamazaki H et al. Risk factors for hepatocellular carcinoma among patients with chronic liver disease. *N Engl J Med* 1993;328(25):1797-1801.

Vauthey JN, Lauwers GY, Esnaola N, Do KA, Belghiti J, Mirza N, Curley SA, Ellis LM, Regimbeau JM, Rashid A, Cleary KR and Nagorney DM. Simplified staging for hepatocellular carcinoma. *J Clin Oncol* 2002;20(6):1527-1536.

Vilana R , Bruix J and Bru C. Tumour size determines the efficacy of PEI for the treatment of small HCC. *Hepatology* 2002 : 16, 353-357.

Vilana R, Bruix J, Bru C et al. Tumour size determines the efficacy of percutaneous ethanol injection for the treatment of small HCC. *hepatology* 1992;16:353-357.

- Vilana R, Bruix J, Bru C, Ayuso C, Sole M and Rodes J.** Tumour size determines the efficacy of percutaneous ethanol injection for the treatment of small hepatocellular carcinoma. *hepatology* 1992 ; 16(2):353-357.
- Villa E, Moles A, Ferretti I , Buttafoco P, Grottola A, Del B uono M , De Santis M and Manenti F.** Natural history of inoperable hepatocellular carcinoma. Oestrogen receptors status in the tumour is the strongest prognostic factor for survival. *hepatology* 2000;32(2)233-238.
- Volg TJ, Trapp M, Schroeder H et al.** Transarterial chemoembolization for HCC. volumetric and morphologic CT criteria for assesment of prognosis and therapeutic success. Results from a liver transplantation center. *radiology* 2000; 214:349-357.
- Yao FY, Ferrell L, Bass NM , Waston JJ, Bacchetti P, Venook A, Ascher NL and Roberts JP.** Liver transplantation for hepatocellular carcinoma. expansion of tumour size limits does not adversely impact survival. *hepatology* 2001 ; 33 (6):1394-1403.
- Yao FY, Ferrell L, Bass NM, Watson JJ, Bacchetti P, Venook A, Ascher NL and Roberts JP.** Liver transplantation for HCC .Expansion of the tumour size limits does not adversely impact survival. *hepatology* 2001;33:1394-403.
- Yao FY, Kinkhabwala M, LaBerge JM, Bass NM, Brown R Jr, Kerlan R, Venook A, Ascher NL, Emond JC and Roberts JP.** The impact of preoperative locoregional therapy on outcome after liver transplantation for HCC. *am J transplant* 2005;5:795-804.
- Yassin Abdul Ghafar , A. Seleem , M. Tawfik , G. Essmat , Ashraf Omar , Abdulla M. Khalil , Abdul Zahar Hassan and Mostafa Kamal.** PEI in large size and multiple lesions of HCC: two years follow up in 165 patients. *Decembre 2002 , vol. 70 , no. 4 , supp. II* , 299-304.

- Yu MC , Yuan JM, Govindarajan S and Ross RK.** Epidemiology of HCC. Can J Gastroenterol 2000 , 14, 703-709.
- Yu MW , Hsu FC and Sheen IS.** Prospective study of HCC and liver cirrhosis in asymptomatic chronic HBV carriers. Am J Epidemiol. 1997 : 145: 1039-1047.
- Yu MW, Chen CJ.** Elevated serum testosterone levels and risk of HCC. cancer res 1993;53:790-794.
- Yu MW, Yeh SH, Chen PJ, Liaw YF, Lin CL, Liu CJ, Shih WL, Kao JH, Chen DS, Chen CJ.** HBV genotype and DNA level and HCC. A prospective study in men. J natl cancer inst 2005; 97:265-272.
- Yu SZ and Chen G.** Blue green algae toxins and liver cancer. china J cancer res. 1994;6:9-17.
- Zhang WH, Zhu SN, Lu SL, Huang YL and Zhao P.** Three dimensional image of hepatocellular carcinoma under focal laser scanning microscope. world J gastroenterology 2000;6:344-347.
- Zhao WH, Ma ZM, Zhou XR, Feng YZ and Fang BS.** Prediction of recurrence and prognosis in patients with hepatocellular carcinoma after resection by use of CLIP score. world J gastroenterology 2002;8:237-242.
- Zhou TL and Yu SZ.** Laboratory study on the relationship between drinking water and hepatoma .Quantitative evaluation using GGT method. china J prev. med. 1990 ; 234:203-5.